Section Arrow
Quote
MEIP.NASDAQ
- MEI Pharma
Quotes are at least 15-min delayed:2024/06/09 13:47 EDT
Last
 2.87
+0.05 (+1.77%)
Day High 
2.8852 
Prev. Close
2.82 
1-M High
3.3117 
Volume 
6.48K 
Bid
2.76
Ask
2.87
Day Low
2.79 
Open
2.86 
1-M Low
2.7293 
Market Cap 
18.79M 
Currency USD 
P/E 0.72 
%Yield 60.98 
10-SMA 2.94 
20-SMA 3.02 
50-SMA 3.27 
52-W High 7.8734 
52-W Low 2.7293 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.92/-9.39
Enterprise Value
30.09M
Balance Sheet
Book Value Per Share
7.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
48.82M
Operating Revenue Per Share
7.33
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GERNGeron Corp4.59+0.7+17.99%-- 
DNAGinkgo Bioworks Holdings0.5141-0.0359-6.53%-- 
NVAXNovavax18.17-1.385-7.08%-- 
MCRBSeres Therapeutics0.614-0.2391-28.03%-- 
BMEABiomea Fusion4.14-7.13-63.27%-- 
Quotes are at least 15-min delayed：2024/06/09 13:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.